Helicobacter Pylori Testing Market - By Test Type, By Method, By End Use - Global Forecast, 2025-2034

Helicobacter Pylori Testing Market Size

The global helicobacter pylori testing market was valued at USD 517.8 million in 2024. The market is expected to grow from USD 557.7 million in 2025 to USD 1 billion in 2034, at a CAGR of 7.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

Global market is fueled by increasing incidence of gastric disease, rising geriatric population, growing demand for point-of-care testing devices, and increasing use of non-invasive diagnostic techniques, boosted by technological advances improving accuracy, ease of use, and early detection of H. pylori infections globally.
 

Leading players in the helicobacter pylori testing market include Abbott, bioMérieux, Bio-Rad Laboratories, Cardinal Health, Coris BioConcept, Quest Diagnostics, and Thermo Fisher Scientific. These companies sustain competitiveness through advanced diagnostic product portfolios, global presence, and continuous research and development investments.
 

The market witness steady growth, growing from USD 411.6 million in 2021 to USD 482.8 million in 2023. The market for helicobacter pylori testing is experiencing consistent growth, fueled by a mix of clinical, demographic, and technological forces. Rising prevalence of gastric conditions, such as peptic ulcers, gastritis, and gastric cancer, all of which are closely linked with H. pylori infection, is one of the key drivers. Given that almost half of the entire population of the world carries the bacterium, there is a growing need for effective and affordable diagnostic tools. Additionally, the growing geriatric population drives the market even higher because older adults are more vulnerable to gastrointestinal infections, thus enhancing the need for regular screening and early detection techniques.
 

Another major driver is the growing demand for point-of-care (POC) testing devices. POC diagnostics offer rapid results, ease of use, and better accessibility in both developed and developing regions, enabling early diagnosis and improved patient management. Additionally, there is a rising adoption of non-invasive diagnostic methods, including stool antigen tests, urea breath tests, and serology-based assays, which provide safer, quicker, and more patient-friendly alternatives to invasive endoscopy-based techniques. These methods are gaining traction among healthcare providers as they improve compliance and reduce procedural risks.
 

Technological advancements also play a vital role in fueling market expansion. Innovations in molecular diagnostics, immunoassays, and automated platforms enhance test sensitivity, specificity, and efficiency, meeting the growing need for precision medicine. Integration of digital health tools, AI-based interpretation, and telemedicine platforms further strengthens market opportunities by expanding accessibility and improving disease monitoring. Combined, these drivers ensure robust and sustainable growth in the Helicobacter pylori testing market, making it a critical segment in global gastrointestinal diagnostics.
 

Helicobacter pylori testing refers to diagnostic methods used to detect the presence of H. pylori bacteria in the stomach, which are linked to gastritis, peptic ulcers, and gastric cancer. These tests include non-invasive approaches like breath, stool, and blood tests, as well as invasive endoscopic biopsy-based techniques.
 

Helicobacter Pylori Testing Market Trends

The rising incidence of gastric ulcers is a key driver that supports the growth of the worldwide H. pylori testing market. Gastric ulcers are closely linked to H. pylori infection, which is known to be one of the main etiological factors for peptic ulcer disease.
 

• With an increasing global burden of gastrointestinal diseases, the need for timely and precise diagnostic methods has been on the rise, thus fortifying the use of H. pylori diagnostic techniques such as urea breath tests, stool antigen tests, and serological tests.
   
• On the microeconomic side, increasing patient awareness, combined with individual-level increasing healthcare spending, is fueling the demand for non-invasive and quick diagnostic tests. Patients are increasingly demanding accurate, affordable, and easy solutions, resulting in hospital, clinic, and even home-care settings being transformed towards sophisticated testing modalities. In addition, pricing strategies by competitive diagnostic companies and the increasing penetration of point-of-care devices have a direct impact on consumer choices, driving increased accessibility and usage of these tests.
   
• At the macroeconomic level, demographic changes, such as the rapid growth of the geriatric population, contribute to the rising incidence of gastric ulcers, since older adults are more susceptible to H. pylori infections and related complications. Furthermore, healthcare infrastructure expansion in emerging economies, along with government initiatives to curb gastric cancer mortality through early detection, has created favorable conditions for market expansion. Rising urbanization and changing dietary habits, which increase susceptibility to gastric disorders, further contribute to market demand.
   
• Overall, the growing prevalence of gastric ulcers highlights the urgent need for timely diagnosis and treatment, reinforcing the critical role of H. pylori testing. Supported by favorable microeconomic trends such as patient affordability and macroeconomic drivers like demographic shifts and healthcare investments, this factor will continue to accelerate market growth worldwide.
   

Helicobacter Pylori Testing Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on test type, the global helicobacter pylori testing market is bifurcated into invasive, and non-invasive. The invasive segment is further segmented into rapid urease test, histology, and HP culture. On the other hand, non-invasive segment is further segmented into serologic test, urea breath test, and stool/fecal antigen test. The invasive segment accounted for 43.2% of the market in 2024 driven by its high diagnostic accuracy through endoscopic biopsy and histological examination.
 

The segment is expected to exceed USD 432.9 million by 2034, growing at a CAGR of 6.7% during the forecast period. On the other hand, non-invasive segment is expected to grow with the fastest CAGR of 7.4%. The segment is propelled by its patient-centric strategy, providing rapid, safe, and inexpensive testing free from endoscopy.
 

• Endoscopic biopsy-based techniques allow for direct visualization and tissue sampling, ensuring accurate detection of bacterial colonization and underlying gastric pathology, such as ulcers and malignancies. This accuracy makes invasive testing the gold standard in complicated cases and in those at high risk for gastric cancer.
   
• Additionally, increasing cases of peptic ulcer disease and the growing geriatric population at risk of serious gastric complications are driving demand. In clinical and hospital settings, invasive techniques are favored for diagnosing infection in symptomatic individuals with alarm features like bleeding or weight loss.
   
• Strong physician reliance on histological examination, coupled with continuous advancements in biopsy techniques and pathology services, ensures the segment’s sustained adoption. These factors collectively drive their large market share and steady growth outlook through 2034.
   
• On the other hand, non-invasive segment is expected to grow with the fastest CAGR during the analysis period. These methods eliminate the need for endoscopy, reducing patient discomfort, procedure costs, and associated risks, making them highly accessible in outpatient and home-care settings. The urea breath test, in particular, is widely recognized for its accuracy, convenience, and suitability for both initial diagnosis and post-treatment monitoring. Rising demand for point-of-care and self-testing solutions further propels adoption, especially in primary care and resource-limited regions.
   
• Increasing awareness of H. pylori’s role in gastric cancer prevention is encouraging early screening, driving demand for rapid, safe, and cost-effective tests. Additionally, healthcare providers increasingly prefer non-invasive approaches for mass screening and preventive care programs. Together, these factors establish non-invasive testing as a key growth engine, projected to outpace invasive methods in CAGR over the forecast period.
   

Based on the method, the helicobacter pylori testing market is bifurcated into laboratory-based tests and point of care (POC) tests. The laboratory-based tests segment dominated the market in 2024 with a revenue of USD 320.7 million.
 

• The laboratory testing segment leads the market because of its precision, reliability, and extensive diagnostic functions. Histology, culture, and serology tests offer in-depth details regarding infection status, bacterial strain, and antibiotic susceptibility, which are essential for effective treatment planning. The rising incidence of gastric ulcers, gastritis, and gastrointestinal disorders related to these have increased demand for accurate laboratory diagnostics.
   
• Moreover, the growing availability of healthcare institutions with sophisticated laboratory infrastructure promotes broad-based use of laboratory-based testing. Macro-economic drivers like increasing healthcare spending and government efforts towards enhanced diagnostic service delivery further propel the market. Microeconomic drivers such as patients demand precise diagnosis and physician dependency on laboratory test reports for decision-making make an important contribution.
   
• On the other hand, the point of care (POC) tests segment also plays a vital role in the market, due to its convenience, rapid results, and patient-centric approach. POC tests, such as urea breath tests, stool antigen tests, and rapid urease tests, allow clinicians to perform diagnostics in outpatient settings or even at home, eliminating the need for specialized laboratory infrastructure.
   
• This enhances patient compliance and facilitates timely treatment, especially in regions with limited access to healthcare facilities. Additionally, technological advancements in POC devices, such as portable analyzers and smartphone-integrated testing kits, are accelerating adoption.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, helicobacter pylori testing market is classified into diagnostic labs, hospitals, clinics and other end users. The diagnostic labs segment is expected to reach USD 463.8 million within the forecast period.
 

• The market for diagnostic labs segment is driven mainly by the rising demand for specialized laboratory testing on account of its precision and reliability. Diagnostic laboratories have high-end instruments and competent personnel who are capable of conducting invasive as well as non-invasive tests for H. pylori, such as rapid urease tests, histology, serologic tests, and urea breath tests.
   
• Increasing awareness regarding early diagnosis of H. pylori infection and related gastric diseases prompts patients and doctors to prefer laboratory-based diagnostics. Also, the surge in demand for regular screening, especially in high-prevalence areas of gastric ulcers and gastritis, is driving the growth of the segment.
   
• Conversely, however, the hospitals segment also plays an important role in the market. Because of their availability of endoscopy suites and in-house lab facilities, hospitals are able to conduct invasive tests such as histology and rapid urease tests with high diagnostic accuracy necessary for critically ill patients with serious gastrointestinal symptoms. Increased incidence of gastric ulcers, gastritis, and other H. pylori-related illnesses among both inpatient and outpatient populations prompts hospitals to implement broad testing regimens.
   
• The availability of multidisciplinary gastroenterology departments and trained staff allows hospitals to manage both diagnosis and subsequent treatment, creating a seamless patient experience. Government initiatives promoting early detection and preventive healthcare further support hospital-based testing.
   

Looking for region specific data?

Download Free PDF

North America Helicobacter Pylori Testing Market
 

The North America market dominated the global helicobacter pylori testing market with a market share of 34.6% in 2024.
 

• North America is led by the advanced healthcare facilities of the region and the widespread presence of diagnostic centers. Sustained high incidence of gastrointestinal diseases, such as gastric ulcers and gastritis, elevates the need for precise H. pylori testing. Increased awareness among healthcare practitioners and patients regarding the relevance of early diagnosis and preventive treatment promotes frequent screening in hospitals and diagnostic centers.
   
• Technologies, counting advanced non-invasive urea breath tests and quick serologic assays, surge testing effectiveness and patient compliance. Moreover, established health insurance coverage across the area lowers out-of-pocket costs, making testing more prevalent. Encouraging government policies and clinical guidelines that recommend H. pylori screening among high-risk populations create more market opportunities for growth.
   

The U.S. helicobacter pylori testing was valued at USD 135.6 million and USD 146 million in 2021 and 2022, respectively. The market size reached USD 165.6 million in 2024, growing from USD 155.9 million in 2023.
 

• The growing incidence of H. pylori-related gastrointestinal conditions, such as peptic ulcers and gastric cancers, fuels the demand for accurate and early diagnosis. Hospitals, clinics, and diagnostic laboratories across the U.S. are increasingly adopting both invasive and non-invasive testing methods, including urea breath tests, rapid urease tests, and stool antigen tests, due to their reliability and patient convenience.
   
• Rising awareness among physicians and patients regarding the link between H. pylori infection and chronic gastrointestinal diseases encourages routine screenings. Additionally, favorable reimbursement policies and insurance coverage facilitate greater access to testing services.
   
• Moreover, the presence of key market players investing in innovation and strategic collaborations further strengthens the U.S. market, driving growth and maintaining its leading position within North America.
   

Europe Helicobacter Pylori Testing Market
 

Europe market accounted for USD 139.8 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Growing awareness among patients and healthcare professionals about the link between H. pylori infections and gastric cancer is encouraging routine testing. Advanced healthcare infrastructure, widespread availability of diagnostic laboratories, and adoption of both invasive and non-invasive testing methods, including urea breath tests and rapid urease tests, further support market growth.
   
• Government initiatives and public health campaigns promoting gastrointestinal health and preventive care are increasing patient participation in screening programs. Additionally, the expansion of private diagnostic networks and technological advancements in automated and high throughput testing solutions enhance efficiency and accessibility.
   
• Increasing medical tourism for specialized gastroenterology services also contributes to the uptake of H. pylori testing in Europe, making the region a lucrative market.
   

Germany dominates the European helicobacter pylori testing market, showcasing strong growth potential.
 

• Germany, being one of the biggest healthcare markets in Europe, dominates the H. pylori testing market due to its developed healthcare system and good quality of medical care. Germany has high incidence rates of gastric disease, which makes doctors as well as patients consider early diagnosis as a priority. Widespread usage of invasive tests, for example, rapid urease tests and histology, and non-invasive tests such as urea breath and serological tests is promoted by Germany's highly developed healthcare infrastructure comprising hospitals, specialized gastroenterology clinics, and diagnostic laboratories.
   
• Preventive healthcare-focused government policies, regular screenings, and patient education programs are further increasing rates of testing. Technological advancements in automated test equipment and high-throughput laboratory systems also shorten turnaround time and enhance diagnostic accuracy, thus driving lab-based testing preference.
   
• Strong reimbursement policies and insurance coverage enhance affordability, while ongoing clinical research and collaborations between healthcare providers and diagnostic companies contribute to steady growth in Germany’s H. pylori testing market.
   

Asia Pacific Helicobacter Pylori Testing Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.9% during the analysis timeframe.
 

• The Asia Pacific helicobacter pylori testing market is growing at a fast pace as a result of the increasing rate of H. pylori infections as well as related gastrointestinal diseases in the region. India, Thailand, and Malaysia have high rates of gastric ulcers, gastritis, and stomach cancer, which are driving demand for precise and timely diagnostic testing.
   
• Growing levels of preventive healthcare and early diagnosis both among doctors and patients further drive market take-up. Growing healthcare infrastructure, such as diagnostic centers, hospitals, and clinics, ensures better access to invasive and non-invasive means of tests.
   

China helicobacter pylori testing market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China represents a major growth hub within the Asia Pacific Helicobacter pylori testing market, fueled by the country’s large population and rising prevalence of gastric disorders. The widespread incidence of H. pylori infections in both urban and rural areas has created significant demand for early diagnosis and treatment.
   
• Government-led initiatives focusing on preventive healthcare, early cancer detection, and national screening programs encourage regular testing, particularly in high-risk populations. The country’s rapidly expanding healthcare infrastructure, including tertiary hospitals, specialized diagnostic centers, and advanced laboratories, enhances access to both invasive and non-invasive testing methods.
   
• Increasing disposable income, growing health awareness, and rising physician recommendations for routine H. pylori testing further stimulate market growth.
   

Latin American Helicobacter Pylori Testing Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Growing awareness regarding early diagnosis and preventive healthcare programs both by government and private agencies are promoting the use of H. pylori testing. Easy access to sophisticated diagnostic centers, especially in urban areas, is facilitating growth in invasive as well as non-invasive testing. The increased number of diagnostic laboratories and hospitals with modern endoscopy and urea breath test devices increases testing capacity.
   
• Moreover, the increasing geriatric age group and increasing prevalence of lifestyle-related gastrointestinal diseases further lead to increased test demand. Coordination among healthcare professionals and insurance providers continues to enhance affordability and availability of tests.
   
• In addition, emphasis on early diagnosis to prevent complications such as gastric cancer encourages patients and practitioners to embrace routine H. pylori screening, further augmenting the overall market growth in Brazil.
   

Middle East and Africa Helicobacter Pylori Testing Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia’s H. pylori testing market growth is driven by the increasing prevalence of gastrointestinal diseases and rising awareness about preventive healthcare practices. Government initiatives, such as national health programs and campaigns for early diagnosis of gastric disorders, encourage widespread testing in hospitals and diagnostic centers.
   
• Advanced healthcare infrastructure, including modern laboratories and gastroenterology departments, enables the adoption of both invasive and non-invasive diagnostic techniques. The country’s expanding private healthcare sector and medical insurance coverage improve access to high-quality testing services.
   
• Additionally, the growing geriatric population and lifestyle changes leading to higher risk of peptic ulcers and gastritis are fueling demand for H. pylori detection. Rising medical tourism in Saudi Arabia also supports market growth, as patients seek accurate and reliable diagnostic services.
   
• Continuous investment in healthcare technology, coupled with government support for research and clinical studies on H. pylori, strengthens the testing market and positions Saudi Arabia as a key growth region in the Middle East and Africa.
   

Helicobacter Pylori Testing Market Share

The market is shaped by a mix of established global leaders and emerging innovators, creating a dynamic and moderately consolidated competitive landscape. Key players such as Abbott, Thermo Fisher Scientific, Roche, Bio-Rad Laboratories, and Quest Diagnostics collectively account for a significant portion of the market share, estimated at around 56%. The global helicobacter pylori testing market exhibits a moderately consolidated competitive structure, where a handful of leading players dominate a significant portion of the revenue, while numerous regional and niche players contribute to market diversity. These market leaders focus on enhancing their testing accuracy, expanding non-invasive diagnostic options, and integrating advanced technologies such as automated platforms and point-of-care devices.
 

Meanwhile, emerging innovators and smaller regional players are gradually capturing market attention by offering cost-effective solutions, rapid testing methods, and customized services for specific patient demographics. This competitive interplay encourages technological advancements, strategic partnerships, and mergers and acquisitions, fostering overall market growth. Additionally, players increasingly leverage collaborations with hospitals, diagnostic laboratories, and research institutions to broaden market reach.
 

The distribution of market share indicates that while global giants maintain dominance through brand recognition and scale, smaller and mid-sized players continue to drive innovation and regional penetration, creating a balanced yet competitive environment across mature and emerging markets.
 

Helicobacter Pylori Testing Market Companies

Prominent players operating in helicobacter pylori testing are as mentioned below:

• Abbott
• BIOHIT
• bioMérieux
• Bio-Rad Laboratories
• Cardinal Health
• CERTEST
• Coris BioConcept
• Gulf Coast Scientific 
• Meridian Biosciences
• Quest Diagnostics
• Quidel Corporation
• Roche
• Thermo Fisher Scientific

•  Abbott

Abbott leads the helicobacter pylori testing market with a share of 14% in 2024. Abbott offers highly accurate and reliable H. pylori diagnostic solutions, including serologic and stool antigen tests. Their products emphasize rapid results, ease of use, and integration with automated laboratory systems. Abbott’s global distribution network and strong clinical support ensure accessibility and consistent performance across hospitals and diagnostic laboratories.
 

•  Thermo Fisher Scientific

Thermo Fisher Scientific provides advanced molecular and immunoassay-based H. pylori testing solutions with high sensitivity and specificity. Their platforms focus on automation, scalability, and laboratory workflow efficiency. The company’s strong research and development capabilities and extensive technical support empower laboratories to deliver timely, reproducible results, enhancing diagnostic confidence and patient management.
 

•  Roche

Roche delivers comprehensive H. pylori diagnostic solutions, including non-invasive tests like urea breath and stool antigen assays. Their USP lies in precision, reliability, and integration with automated laboratory instruments. Roche leverages strong global reach, robust clinical validation, and innovative technologies to enable fast, accurate detection and improved patient care.
 

Helicobacter Pylori Testing Industry News

• In July 2025, Bio-Rad launched Platelia H. Pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies. Serology offers a non-invasive, simple, and reliable method for detecting H. pylori infection. The Platelia H. Pylori IgG assay is specifically used to assess the presence and quality of IgG antibodies.
   
• In December 2023, Biomerica, Inc. announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect Stool Antigen ELISA test, designed to detect H. pylori bacteria. This approval strengthened the company’s market position and enhanced its competitiveness.
   
• In July 2023, Meridian Bioscience, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Premier HpSA FLEX for diagnosing H. pylori in both preserved and unpreserved stool samples. This approval broadened the company’s product portfolio and expanded its customer base.
   

The helicobacter pylori testing market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Invasive
  • Rapid urease test           
  • Histology
  • HP culture   
• Non-invasive 
  • Serologic test
  • Urea breath test
  • Stool/fecal antigen test  

Market, By Method

• Laboratory based tests
• Point of care (POC) tests

Market, By End Use

• Diagnostic labs 
• Hospitals
• Clinics   
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE